Zynex (ZYXI)
(Real Time Quote from BATS)
$10.54 USD
+0.02 (0.19%)
Updated May 28, 2024 09:40 AM ET
2-Buy of 5 2
A Value B Growth F Momentum B VGM
Brokerage Reports
Zynex Inc. [ZYXI]
Reports for Purchase
Showing records 21 - 40 ( 93 total )
Company: Zynex Inc.
Industry: Medical - Products
Enrollment Starts in Clinical Trial of Fluid Monitoring System; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Company: Zynex Inc.
Industry: Medical - Products
Order Growth Remains Strong in 3Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Company: Zynex Inc.
Industry: Medical - Products
2Q21 Earnings Beat; 2021 Guidance Lowered; Reducing PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Company: Zynex Inc.
Industry: Medical - Products
In-Line 1Q21 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Company: Zynex Inc.
Industry: Medical - Products
Robust Growth in 4Q and Full-Year 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Sepsis Monitor Patent Application; Robust 4Q20 Order Growth; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
3Q20 Financial Results; Top- and Bottom-Line In-Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Order Growth Slightly Soft vs. Expectation in 3Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Manufacturing and Inventory Capacity Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Robust Order Growth; Sales Team Strengthened; Upgrading to Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Strong July - August Order Growth; Continue to Recommend Purchase
Provider: Piper Sandler
Analyst: Research Department
Company: Zynex Inc.
Industry: Medical - Products
2Q20 Financials; COVID-19 Shrinks Prescriber Pool; Reiterate Neutral; Lowering PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Strong Order Growth in 2Q20; Guidance Raised; Reiterate Neutral; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Pleasant Run to Fair Valuation; Downgrading to Neutral; Maintaining $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Robust 1Q20 Financial Performance; Reiterate Buy; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Zynex Inc.
Industry: Medical - Products
Strong 1Q20 Order Growth; Guidance Raised, Despite Pandemic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y